Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2011, Article ID 314970, 7 pages
http://dx.doi.org/10.4061/2011/314970
Research Article

Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational Study

1Departments of Psychiatry and Behavioral Sciences, Sociology, and Psychology and Neuroscience, Duke University Medical Center, Durham, NC 27710, USA
2Washington University School of Medicine, St. Louis, MO 63110, USA
3Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA

Received 4 April 2011; Accepted 23 June 2011

Academic Editor: David L. Kendler

Copyright © 2011 Deborah T. Gold et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Osteoporosis Foundation, Clinician's Guide to the Prevention and Treatement of Osteoporosis, National Osteoporosis Foundation, Washington, DC, USA, 2008.
  2. J. Y. Reginster, V. Rabenda, and A. Neuprez, “Adherence, patient preference and dosing frequency: understanding the relationship,” Bone, vol. 38, no. 4, pp. S2–S6, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Y. Reginster, “Adherence and persistence: impact on outcomes and health care resources,” Bone, vol. 38, no. 2, pp. S18–S21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Weycker, D. Macarios, J. Edelsberg, and G. Oster, “Compliance with drug therapy for postmenopausal osteoporosis,” Osteoporosis International, vol. 17, no. 11, pp. 1645–1652, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Weycker, D. Macarios, J. Edelsberg, and G. Oster, “Compliance with osteoporosis drug therapy and risk of fracture,” Osteoporosis International, vol. 18, no. 3, pp. 271–277, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. S. McCombs, P. Thiebaud, C. McLaughlin-Miley, and J. Shi, “Compliance with drug therapies for the treatment and prevention of osteoporosis,” Maturitas, vol. 48, no. 3, pp. 271–287, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. T. W. Downey, S. H. Foltz, S. J. Boccuzzi, M. A. Omar, and K. H. Kahler, “Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting,” Southern Medical Journal, vol. 99, no. 6, pp. 570–575, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Cramer, D. T. Gold, S. L. Silverman, and E. M. Lewiecki, “A systematic review of persistence and compliance with bisphosphonates for osteoporosis,” Osteoporosis International, vol. 18, no. 8, pp. 1023–1031, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. A. N. A. Tosteson, M. R. Grove, C. S. Hammond et al., “Early discontinuation of treatment for osteoporosis,” American Journal of Medicine, vol. 115, no. 3, pp. 209–216, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Sebaldt, L. G. Shane, B. Pham, R. Cook, L. Thabane, and A. Petrie, “Long-term effectiveness outcomes of non-compliance and non-persistence with daily regimen bisphoshonate therapy in patients with osteoporosis treated in tertiary specialist care,” Osteoporosis International, vol. 15, p. S107, 2004, Abstract P391SA. View at Google Scholar
  11. R. Eastell, P. Garnero, L. Vrigens, L. Van de Langerijt, H. A. P. Pols, and J. D. Ringe, “Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study,” Calcified Tissue International, vol. 72, p. 408, 2003, Abstract P297. View at Google Scholar
  12. Forteo [package insert], Eli Lilly and Company, Indianapolis, Ind, USA, 2010.
  13. P. D. Miller, S. L. Silverman, D. T. Gold, K. A. Taylor, P. Chen, and R. B. Wagman, “Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study,” Osteoporosis International, vol. 17, no. 1, pp. 85–90, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Brod, M. Rousculp, and A. Cameron, “Understanding compliance issues for daily self-injectable treatment in ambulatory care settings,” Patient Prefer Adherence, vol. 2, pp. 129–136, 2008. View at Google Scholar
  15. S. A. Foster, K. A. Foley, E. S. Meadows et al., “Characteristics of patients initiating teriparatide for the treatment of osteoporosis,” Osteoporosis International, vol. 19, no. 3, pp. 373–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. E. S. Meadows, M. Rousculp, A. C. Sasser et al., “Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance,” Current Medical Research and Opinion, vol. 23, no. 12, pp. 3215–3222, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. National Osteoporosis Foundation, America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation, National Osteoporosis Foundation, Washington, DC, USA, 2010.
  18. J. A. Kanis, A. Oden, O. Johnell et al., “The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women,” Osteoporosis International, vol. 18, no. 8, pp. 1033–1046, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. N. K. Arden, S. Earl, D. J. Fisher, C. Cooper, S. Carruthers, and M. Goater, “Persistence with teriparatide in patients with osteoporosis: the UK experience,” Osteoporosis International, vol. 17, no. 11, pp. 1626–1629, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Briot, P. Ravaud, P. Dargent-Molina, M. Zylberman, S. Liu-Leage, and C. Roux, “Persistence with teriparatide in postmenopausal osteoporosis; Impact of a patient education and follow-up program: The French experience,” Osteoporosis International, vol. 20, no. 4, pp. 625–630, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. B. L. Langdahl, G. Rajzbaum, F. Jakob et al., “Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS),” Calcified Tissue International, vol. 85, no. 6, pp. 484–493, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. R. M. Neer, C. D. Arnaud, J. R. Zanchetta et al., “Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis,” New England Journal of Medicine, vol. 344, no. 19, pp. 1434–1441, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Fraser, O. Hadjimichael, and T. Vollmer, “Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis,” The Journal of Neuroscience Nursing, vol. 33, no. 5, pp. 231–239, 2001. View at Google Scholar · View at Scopus
  24. S. Schwartzman and G. J. Morgan Jr., “Does route of administration affect the outcome of TNF antagonist therapy?” Arthritis Research and Therapy, vol. 6, no. 2, pp. S19–S23, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. O. Bock and D. Felsenberg, “Bisphosphonates in the management of postmenopausal osteoporosis—optimizing efficacy in clinical practice,” Clinical Interventions in Aging, vol. 3, no. 2, pp. 279–297, 2008. View at Google Scholar · View at Scopus
  26. W. Yin, A. Basu, J. X. Zhang, A. Rabbani, D. O. Meltzer, and G. C. Alexander, “The effect of the medicare part D prescription benefit on drug utilization and expenditures,” Annals of Internal Medicine, vol. 148, no. 3, pp. 169–177, 2008. View at Google Scholar · View at Scopus